CMND
Clearmind Medicine Inc. (CMND) 10Y Growth Potential Analysis (2026)
No material changes this month.
Revenue Growth Drivers
No disclosed 5-year revenue, EPS, or FCF CAGR limits evidence of repeatable compounding versus peers with measurable multi-year growth records.
Negative TTM ROIC suggests incremental capital has not yet translated into scalable revenue expansion, unlike stronger peers that reinvest profitably.
Zero reported capex-to-revenue may reflect limited reinvestment intensity, reducing visible capacity to fund sustained organic or inorganic growth.
Extremely negative cash conversion cycle appears data-distorted, but it does not provide peer-leading proof of durable growth generation.
Market Tailwinds
Available metrics do not show a clear demand tailwind, leaving long-term revenue expansion less evidenced than peers with documented multi-year growth momentum.
No segmentation concentration data is provided, so the company lacks demonstrated cross-sell or share-of-wallet expansion evidence versus more diversified peers.
Negative profitability and weak cash returns imply the current market position has not yet converted into durable growth economics.
Low EV-to-sales data quality limits inference, but it still does not establish a stronger growth runway than comparable listed peers.
Scalability Expansion
Negative ROIC indicates scaling has not yet produced attractive incremental returns, whereas stronger peers typically compound revenue with positive reinvestment economics.
Net debt to EBITDA is moderate, but leverage still reduces flexibility relative to peers with cleaner balance sheets and greater expansion capacity.
Interest coverage is deeply negative, signaling current earnings do not support scalable expansion from internal cash generation.
The absence of segment and geographic growth data prevents evidence of platform-like scaling seen in more expandable peer models.
Constraints Limitations
Negative ROIC is the clearest structural constraint because it limits self-funded expansion and weakens long-term compounding versus profitable peers.
Negative interest coverage indicates financing dependence, which can cap growth investment capacity relative to peers with stronger operating coverage.
Missing multi-year growth disclosures reduce visibility, making it harder to evidence durable scaling compared with peers that report consistent CAGR trends.
The current metrics suggest constrained growth capacity, although the data quality issues prevent assigning an even lower structural score.
Overall Score
CMND shows limited evidence of durable long-term compounding, with negative ROIC and weak coverage metrics outweighing any unproven expansion potential versus peers.
Score Driver: Negative Roic
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Clearmind Medicine Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
